Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Pegaptanib Sodium on Foveal Thickening in Patients with Exudative Subfoveal Age-related Macular Degeneration (AMD)
This study is currently recruiting patients.
Sponsored by: | Eyetech Pharmaceuticals
Pfizer
|
---|---|
Information provided by: | Eyetech Pharmaceuticals |
Purpose
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
Condition | Treatment or Intervention | Phase |
---|---|---|
Macular Degeneration |
Drug: Macugen ™ (pegaptanib sodium injection) |
Phase II |
MedlinePlus related topics: Macular Degeneration
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study
Official Title: A Phase II Prospective, Randomized, Double-masked, Sham-controlled, Dose-ranging, Multi-center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients with Exudative Subfoveal Age-related Macular Degeneration (AMD)
Expected Total Enrollment: 135
Study start: March 2004
This will be a randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups. Patients will be stratified by clinical center and foveal thickness to be treated either Macugen or a sham injection. After 24 weeks, all patients will treated with Macugen until the end of the study at 54 weeks.
Eligibility
Ages Eligible for Study: 50 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |